Press release
Antibody research company Kymab implements ConturELN
STOCKHOLM, Sweden, March 21st, 2011. – The Cambridge-based biopharmaceutical company Kymab has implemented the Electronic Laboratory Notebook system ConturELN. The system will be used for research documentation and knowledge sharing, and to allow the rapid assessment of progress in order to streamline the company’s R&D process.Founded in 2009, Kymab is a biopharmaceutical company engaged in the discovery and development of human monoclonal antibody therapeutics. By using its proprietary KymouseTM platform, research is expected to lead to the discovery of highly potent therapeutic antibodies with excellent affinities and neutralizing capability, previously only possible through in vitro and in vivo technologies in the industry.
As a new, dynamic and fast moving company Kymab needed to adopt the most efficient methods of recording their experimental work in order to allow the rapid assessment of progress, to identify road-blocks and capitalize on the talented scientists that are part of their team.
Several Electronic Laboratory Notebook solutions were thoroughly evaluated before ConturELN was chosen, as providing the right balance between functionality with an easy learning curve and enterprise features such as IP witnessing and Oracle support etc.
“We have focused at an early stage on the ability to access and perpetuate valuable research material in an electronic format. This will allow us to leverage our data to the best possible extent across a variety of research and development projects. Our scientists are enthusiastic about using an electronic laboratory notebook solution. Contur ELN provides an excellent balance between rich-content and usability”, says Mark Strivens, Vice President, Bioinformatics at Kymab.
“We are pleased to welcome Kymab on board as customers. This further confirms that ConturELN is an optimal solution for biopharma companies looking for a robust and secure yet user friendly and cost effective ELN solution”, says Thomas Rozlucki, CEO at Contur Software.
About Kymab Limited
Kymab is a biopharmaceutical company engaged in the discovery and development of human monoclonal antibody therapeutics. Despite the prevalence and importance of the monoclonal antibody class of drugs, the industry has been relying on in vitro and in vivo technologies to generate antibodies that are not optimal and do not adequately replicate the full potential of the human immune system. Kymab is creating a mouse-based antibody discovery technology, the KymouseTM, with a superior repertoire of B-cell mediated immune response that is expected to lead to the discovery of highly potent therapeutic antibodies with excellent affinities and neutralizing capability.
About Contur Software
Contur Software is a focused software company delivering electronic lab notebook solutions to R&D organizations worldwide. The core product, ConturELN, is an enterprise ELN solution designed for implementation across all scientific disciplines providing one common platform for collaboration and IP protection. Customers include leading Pharma/Biotech, Food & Beverage and Materials/Chemicals companies. Information on Contur Software is available at www.contur.com.
Media Contacts:
Thomas Rozlucki, CEO, Contur Software AB
Birger Jarlsgatan 33, 11145 Stockholm, Sweden
Phone: +46 (0)8 663 7000
E-mail: thomas.rozlucki@contur.com
Andrew P Sandham, Chairman & CEO, Kymab Ltd
Meditrina, Babraham Research Campus, Cambridge CB22 3AT, UK
Phone: +44 (0)1223 833301
E-mail: andrew.sandham@kymab.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Antibody research company Kymab implements ConturELN here
News-ID: 167408 • Views: …
More Releases from Contur Software AB
Contur Software delivers cloud based ELN solution to chemistry research company …
STOCKHOLM, Sweden, July 8th, 2011. – Contur Software AB, a wholly owned subsidiary of Accelrys, Inc (NASDAQ:ACCL), today announced that compound supplier Key Organics Ltd. has chosen the cloud solution iLabber as their Electronic Laboratory Notebook system. iLabber will be used within early drug discovery research to improve research documentation and knowledge sharing and reinforce IP protection in contract research.
Key Organics is a leading global provider in the supply of…
CONTUR SOFTWARE PARTNERS WITH HEINZ NORTH AMERICA ON NEW ELECTRONIC LAB NOTEBOOK …
STOCKHOLM, Sweden, February 10th, 2010. – Contur Software today announced its partnership with Heinz North America to implement a new electronic lab notebook system, ConturELN, across Heinz’s U.S. research and development organization. The system will be used to better facilitate research documentation and improve knowledge sharing throughout product development and packaging innovation.
“We’re excited to partner with Heinz to leverage the ConturELN technology and to help them maintain their presence…
Contur Software awarded prestigious contract from Mount Sinai School of Medicine
STOCKHOLM, Sweden, December 28th, 2010. – Contur Software joins PRIME, a Research Program funded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the US National Institutes of Health (NIH), as informatics partner. The goal of PRIME is to develop a platform for improved modeling of immune processes.
PRIME (Program for Research on Immune Modeling and Experimentation) is a research collaboration between Mount Sinai School of Medicine, Princeton…
iLabber selected by research group at Yale’s Chemistry Department
STOCKHOLM, Sweden, October 27, 2010. – Contur Software today announced that Professor Andrew Phillips’ research group at the Department of Chemistry at Yale University has selected iLabber as their Electronic Lab Notebook system.
Professor Phillip’s group study biologically active natural products – from total synthesis and biological function to the identification of smaller molecules with similar biological effects. The broader work of the group required a flexible ELN whilst maintaining…
More Releases for Kymab
Antibody Discovery Platforms Market Study for 2022 to 2028 Providing Information …
Los Angeles, United State: The report on the global Antibody Discovery Platforms market has been prepared by experienced and knowledgeable market analysts and researchers. It is a phenomenal compilation of important studies that explore the competitive landscape, segmentation, geographical expansion, and revenue, production, and consumption growth of the global Antibody Discovery Platforms market. Players can use the accurate market facts and figures and statistical studies provided in the report to…
Antibody Discovery Platforms Market Trends and Forecast Report 2022 | By Players …
The QY Research released a latest market research report on the global and United States Antibody Discovery Platforms market, which is segmented by region (country), players, by Type and by Application. Players, stakeholders, and other participants in the global Antibody Discovery Platforms market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by region (country), by…
Premix Insulin Market 2021 Industry Analysis, Segmentation, Share, Size, Opportu …
The Premix Insulin Market research report added by MarketInsightsReports is an in-depth analysis of the latest trends, market size, status, upcoming technologies, industry drivers, challenges, regulatory policies, with key company profiles and strategies of players. The research study provides market introduction, Premix Insulin market definition, regional market scope, sales and revenue by region, manufacturing cost analysis, Industrial Chain, market effect elements analysis, Premix Insulin market size forecast, 100+ market data,…
Monoclonal Antibodies Market 2021 : Latest Development Pfizer, Novartis AG, Baye …
Global Monoclonal Antibodies Market, by Source (Human, Chimeric, Murine, and Humanized), by Application (Cancer, Autoimmune Disease, Hematological Disease, Infectious Disease, and Others), by Distribution Channel (Hospital Pharmacy, Retail Pharmacy, and Online Pharmacy), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa), is estimated to be valued at US$ 143.5 billion in 2020 and is expected to exhibit a CAGR of 14.4% over the forecast period…
Monoclonal Antibodies Market Outline and Updates..!!
Rising adoption of strategies such as acquisition, collaboration, and license agreement by the market players is expected to bolster the monoclonal antibodies market growth over the forecast period. For instance, in 2018, F. Hoffman-La Roche AG and Kymab Group Ltd entered into a clinical trial agreement to evaluate KY1044 (product of Kymab Group), a human monoclonal antibody, for the treatment of solid tumors. Also, in 2018, Novartis AG entered into…
Impact of Coronavirus (Covid-19) On Monoclonal Antibodies Market Rapidly Develop …
The coronavirus (COVID 19) pandemic and lockdown in various countries across the globe have impacted the financial status of businesses in all sectors. The lockdown in various countries due to the pandemic has placed an economic burden on the healthcare sector. The guidelines issued by the U.S. Food and Drug Administration (FDA) include general considerations to assist sponsors and researchers, which ensure the safety of trial participants, compliance with good…
